IVIg to Treat BK Viremia in Kidney Transplant Recipients

Summary

The overall goal of this study is to rapidly improve clearance of BK viremia with Immunoglobulin (Privigen®) thereby decreasing the potential for formation of alloantibodies in renal transplant recipients that have had immunosuppression reduction due to BK viremia. Our approach is to perform a prospective, randomized, placebo controlled trial intravenous immune globulin (IVIg; Privigen®) plus protocolized immunosuppression reduction versus placebo and protocolized immunosuppression reduction in patients with BK viremia post-kidney transplantation.

Timeline

Start

2016-05

Primary completion

2020-12-10

Completion

2021-03-31

Publications

• He KD, Gressens SB, Dadhania DM, Gilligan HM, Davis C, Edusei E, Ahn J, Lifton M, Pastrana DV, Kleiboeker S, Buck CB, Jost S, Wojciechowski D, Tan CS. Immune Responses to BK Virus in Renal Transplant Recipients Receiving Intravenous Immunoglobulin Treatment. J Infect Dis. 2026 Feb 18;233(2):e392-e403. doi: 10.1093/infdis/jiaf525.

Drugs

Indications